| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Polyether F127 Diacrylate does not target specific receptors; it is a biomaterial scaffold. The acrylate groups crosslink rapidly under UV or visible light in the presence of a photoinitiator (e.g., LAP). The resulting hydrogel provides a 3D matrix that supports cell adhesion, proliferation, and differentiation. The thermo‑gelling behavior (micellization) is used for injectable formulations that gel at body temperature.
|
|---|---|
| ln Vitro |
In vitro, Polyether F127 Diacrylate is used to fabricate hydrogels for 3D cell culture. F127DA (5-20% w/v) is dissolved in PBS with a photoinitiator (e.g., 0.1% LAP). A cell suspension is mixed with the precursor solution, and the mixture is exposed to 365 nm UV or 405 nm visible light (5-20 mW/cm2, 30-60 s) to form a cell‑encapsulating hydrogel. Cell viability is typically >90% after encapsulation. The hydrogel supports long‑term (14‑28 day) culture of primary cells, including neurons, stem cells, and cancer cells.
|
| ln Vivo |
Polyether F127 Diacrylate is not a drug; it is used as an implantable or injectable scaffold in animal models. For in vivo evaluation, a F127DA precursor solution (10% w/v, with 0.1% LAP and growth factors as needed) is injected subcutaneously into mice. The solution is irradiated through the skin (e.g., with a handheld UV lamp) for 30-60 s to form an in situ hydrogel. The gel is well‑tolerated for up to 28 days with minimal inflammation. The scaffold promotes neovascularization and supports encapsulated cell survival.
|
| Enzyme Assay |
The crosslinking efficiency of F127DA is assessed by rheology. A 10% w/v F127DA solution containing 0.1% LAP is placed on a rheometer stage with a quartz plate. The sample is irradiated with 365 nm UV light (10 mW/cm2) for 60 s at 37 degC. The storage modulus (G') and loss modulus (G'') are measured as a function of time. G' increases from <10 Pa (solution) to >1000 Pa (gel) within 60 s. The gel remains stable for >1 h. Swelling ratio is measured after crosslinking.
|
| Cell Assay |
For 3D cell encapsulation, cells (1×10⁶/mL) are suspended in 10% F127DA/0.1% LAP precursor solution in PBS. A 50‑microL droplet is placed on a glass slide and covered with a coverslip. The droplet is irradiated with 405 nm light (10 mW/cm2, 60 s) through the coverslip. The gel‑encapsulated cells are cultured in media for 7-14 days. Cell viability is assessed by Live/Dead staining (calcein‑AM/PI) at multiple time points. Cell proliferation and morphology are imaged by confocal microscopy.
|
| Animal Protocol |
For in situ gel formation, an animal is anesthetized, and a 100‑microL aliquot of F127DA/LAP precursor solution is injected subcutaneously into the dorsum of an 8‑week‑old mouse. The injection site is immediately irradiated through the skin with a 405 nm LED lamp (10 mW/cm2, 60 s). The animal is allowed to recover. At 7, 14, and 28 days post‑injection, the mouse is euthanized, and the gel is harvested for histological analysis (H&E, Masson's trichrome) to assess biocompatibility and tissue integration.
|
| ADME/Pharmacokinetics |
Polyether F127 Diacrylate is not a drug; its PK properties are not defined. After subcutaneous implantation, the hydrogel degrades slowly over 4-8 weeks, with degradation products (PEG, PPG, polyacrylic acid) cleared by renal excretion. The rate of degradation can be tuned by the polymer concentration and crosslinking density. The gel itself remains at the injection site and does not distribute systemically; therefore, PK parameters (Cmax, Tmax, AUC) are not applicable.
|
| Toxicity/Toxicokinetics |
F127DA is a biocompatible material. In vivo studies in mice show no systemic toxicity, organ damage, or abnormal weight loss after subcutaneous implantation of F127DA hydrogels for 28 days. Local inflammation (mild, transient) resolves within 14 days. No acute oral toxicity data are available. As a polymer, F127DA has an LD₅0 >5000 mg/kg in rats. Skin and eye contact should be avoided; wear gloves and goggles. The photoinitiator LAP is also non‑toxic at used concentrations.
|
| References | |
| Additional Infomation |
Polyether F127 Diacrylate is not a drug; it is a research‑only biomaterial for tissue engineering, 3D bioprinting, drug delivery, and wound dressing applications. Its thermo‑gelation and UV‑crosslinking properties make it a versatile scaffold for in vitro and in vivo studies. F127DA has been used for culturing neural stem cells, cardiomyocytes, and tumor spheroids. It is not FDA‑approved for clinical use but is widely employed in preclinical research due to its excellent biosafety record.
|
| Appearance |
White to off-white solid powder
|
|---|---|
| Synonyms |
F127DA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
